• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Clinical Application of Anti-angiogenetic Therapy on Hepatocarcinogenesis and Hepatocellular carcinoma -With Special Reference to Matrix Metalloproteinases and Cytokines network-

Research Project

Project/Area Number 12671268
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionJikei University School of Medicine

Principal Investigator

ISHII Yuji  Jikei University School of Medicine, Dept. of surgery,.Assistant Professor, 医学部, 講師 (40212831)

Co-Investigator(Kenkyū-buntansha) YASUDA Takeshi  Jikei University School of Medicine, Dept. of surgery,.Instructor, 医学部, 助手 (70318004)
OGAWA Ryunosuke  Jikei University School of Medicine, Dept. of surgery,.Instructor, 医学部, 助手 (10246382)
NAKASATO Yuichi  Jikei University School of Medicine, Dept. of surgery,.Assistant Professor, 医学部, 助手 (30266655)
Project Period (FY) 2000 – 2001
Project Status Completed (Fiscal Year 2001)
Budget Amount *help
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2001: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2000: ¥2,300,000 (Direct Cost: ¥2,300,000)
KeywordsMatrix Metalloproteinase / VEGF / Angiogenesis / Cytokine / Chemoprevention / Hepatocellular carcinoma / Angiogenetic therapy / chemoprevention
Research Abstract

To purpose of this study is to control a tumor-related angiogenesis of hepatocellular carcinoma (HCC). In this particular study, angiogenesis-related matrix metallojroteinases (MMPs), vascular endothelial growth factor (VEGF) and angiogenesis-related cytokines network were forcused. In the examination using a diethylnitrosamine-induced rat HCC model, enhanced expression of MMP-2 and MT1-MMP, compatibility of these sites and enhanced expression of MMP-9 in HCC invasive lesion were observed together with its fibronation and carcinogenesis. In clinical cases, enhanced expression of MMP-7 was interestingly observed in HCC viable cells after transcatheter arterial embolization with its suspected involvement in the proliferation of MMP-3,7 in addition to similar results as those described above. Furthermore, MT1 -MMP seemed to be a key factor of HCC. It was noteworthy in the correlation of VEGF and MMPs that compatibility of VEGF and MMP-9 was often observed. In clinical cases, decreased IFN-γ and increased IL-8 were characteristically observed before and after carcinogenesis. it was also suggested from in vitro studies that I-ICV has a close relation to angiogenesis in particular. In the fundamental study, MMP inhibitor and vascular endothelial proliferation inhibitor showed tumor dormancy, tumor shrinkage and chemoprevention effects on HCC. The clinical application of antiangiogenetic therapy is greatly expected.

Report

(3 results)
  • 2001 Annual Research Report   Final Research Report Summary
  • 2000 Annual Research Report
  • Research Products

    (3 results)

All Other

All Publications (3 results)

  • [Publications] Y.Ishii, Y.Nakasato, T.Aoki: "New Strategy for Hepatocellular Carcinoma For Clinical Application of Matrix Metalloproteinase Inhibitor"Microcirculation. Vol.7. 391-396 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Y. Ishii, Y Nakasato, and T. Aoki.: "New strategy for Hepatocellular Carcinoma ・For Clinical Application of Matrix Metalloproteinase Inhibitor・"Microcirculation. Vol.7. 391-396 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Y.Ishii, Y.Nakasato, T.Aoki.: "New Strategy for Hepatocellular Carcinoma For Clinical Application of Matrix Metalloproteinase Inhibitor"Microcirculation. Vol.7. 391-396 (2001)

    • Related Report
      2001 Annual Research Report

URL: 

Published: 2000-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi